WikiTrademarks - Search, analyse, and monitor trademark applications.

Trademark: ACQUIRE ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE

Mark Identification

ACQUIRE ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE

Click here to search for trademarks similar to ACQUIRE ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE

Proof of use for ACQUIRE ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE

We do not have any records of a proof of use for ACQUIRE ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE at this moment.

Click here to add a proof of use for ACQUIRE ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE

Possible trademark infringements of ACQUIRE ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE

Basic Information about ACQUIRE ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE

Serial Number
86437926
Filing Date
29 Oct 2014
Registration Number
5469931
Registration Date
15 May 2018
Mark Drawing Code
4

Classifications

Declare the trademark use of ACQUIRE ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE on the blockchain with WikiTrademarks.io.

First use of ACQUIRE ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE anywhere
ACQUIRE ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE was first used on 31 Oct 2011 for the primary classification of goods and services, international, 042 (Computer, scientific & legal)
First use in commerce
There is no first use of this trademark in commerce detected yet.
Status Code
6
International Code
042
US Codes
100; 101

Who owns ACQUIRE ABATACEPT COMPARISON OF SUB(QU)CUTANEOUS VS. INTRAVENOUS IN INADEQUATE RESPONDERS TO METHOTREXATE?

Correspondent

Marilyn F. Kelly
Bristol-Myers Squibb Company
P.O. Box 4000
Trademark Dept., Mailstop D4243